Download PDF

1. Company Snapshot

1.a. Company Description

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally.The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older.It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia.


The company was formerly known as Aytu BioScience, Inc.and changed its name to Aytu Biopharma, Inc.in March 2021.


Aytu Biopharma, Inc.was incorporated in 2015 and is headquartered in Englewood, Colorado.

Show Full description

1.b. Last Insights on AYTU

Aytu BioPharma's recent performance was negatively impacted by a lack of significant revenue growth, despite a 86% sequential increase in Pediatric Portfolio net revenue. The company's Adjusted EBITDA of $1.3 million was lower than expected, and its net income of $0.8 million was also below forecast. Additionally, the company's cash balance of $20.4 million at December 31, 2024, may not be sufficient to support its future growth plans.

1.c. Company Highlights

2. Aytu BioPharma's Q2 Fiscal 2026 Earnings: ExuA Launch Off to a Strong Start

Aytu BioPharma reported a net revenue of $15.2 million for the second quarter of fiscal 2026, a decline from $16.2 million in the prior year, primarily due to decreased ADHD portfolio revenue. The ADHD portfolio generated $13.2 million in net revenue, a slight decrease from the year-ago period and flat compared to Q1. Gross margin was 63.5%, down from 66.5% last year, mainly due to ExuA launch expenses and a $600,000 inventory write-down. The company reported a net loss of $10.6 million, or $1.05 per share, compared to a net income of $800,000, or $0.13 per share, in the prior year. Adjusted EBITDA was a negative $800,000, down from a positive $1.3 million in the year-ago period.

Publication Date: Feb -09

📋 Highlights
  • Revenue Decline:: Net revenue fell to $15.2M YoY (-6.2%), driven by a $1M drop in ADHD portfolio revenue ($13.2M vs. $14.2M prior year) due to generic competition and ExuA shift.
  • Pediatric Portfolio Growth:: Revenue surged to $1.7M in Q2 from $715K in Q1, a 138% increase, signaling potential diversification beyond ADHD.
  • Gross Margin Pressure:: Gross margin dipped to 63.5% from 66.5%, impacted by $600K inventory write-down and ExuA launch costs.
  • ExuA Launch Progress:: Early adoption with 100+ prescribers and refills via RxConnect, though initial $10M budget reduced to under $8M, including $3M one-time costs.
  • Financial Challenges:: Net loss of $10.6M ($1.05/share) vs. $0.8M profit YoY, with operating expenses up to $11.1M and cash reserves of $30M as of Q1 2026.

ExuA Launch Progress

The commercial launch of ExuA for major depressive disorder is off to a strong start, with over 100 doctors writing prescriptions and early enthusiasm from the field. The company has a comprehensive launch plan focused on prescriber adoption and brand growth, with an initial launch investment budget of $10 million reduced to under $8 million, with about $3 million in one-time items. As per the management, "the launch has faced some challenges, including severe weather conditions that have impacted prescription fills and sales representative productivity." However, the company has adequate supply to meet demand and is well-positioned to scale up production if needed.

Financial Outlook and Valuation

Aytu BioPharma expects a gross margin of around 69% and a net revenue growth that will be impacted by a no-cost guarantee program, which will lower net revenues until month three refills occur. The company anticipates quarterly operating expenses to reach $11.6 million, with about $0.5 million in non-cash expenses, and a cash breakeven point of $16.6 million per quarter. With a current P/S Ratio of 0.31, the market seems to have moderate expectations from the company. Analysts estimate next year's revenue growth at 43.0%, indicating potential upside. The current valuation metrics, including a P/E Ratio of -0.98 and an EV/EBITDA of -0.72, suggest that the market has already priced in some level of improvement in the company's financial performance.

Cash Position and Future Plans

Aytu BioPharma had $30 million in cash and cash equivalents as of December 31, 2025, providing a sufficient runway for the company to execute its launch plan. Management is judicious about expansion, and any increase in sales force will be triggered by cash flow supporting it, with no plan to raise capital for this specific purpose. The company has also engaged in early-stage direct-to-consumer marketing efforts, including web-based campaigns, search engine optimization, and social media outreach, to drive adoption of ExuA.

3. NewsRoom

Card image cap

Aytu BioPharma Inc. (NASDAQ:AYTU) Receives Consensus Recommendation of “Hold” from Analysts

Feb -16

Source: defenseworld.net

Card image cap

Aytu BioPharma, Inc. (AYTU) Q2 2026 Earnings Call Transcript

Feb -04

Source: seekingalpha.com

Card image cap

Aytu BioPharma Inc. (AYTU) Reports Q2 Loss, Beats Revenue Estimates

Feb -04

Source: zacks.com

Card image cap

Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results

Feb -03

Source: accessnewswire.com

Card image cap

New Strong Sell Stocks for February 2nd

Feb -02

Source: zacks.com

Card image cap

Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026

Jan -27

Source: accessnewswire.com

Card image cap

Aytu BioPharma Inc. (NASDAQ:AYTU) Given Average Recommendation of “Hold” by Brokerages

Jan -22

Source: defenseworld.net

Card image cap

Aytu BioPharma, Inc. (AYTU) Analyst/Investor Day Transcript

Jan -21

Source: seekingalpha.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (3.00%)

6. Segments

Aytu Bioscience

Expected Growth: 3.0%

Aytu Bioscience's 3.0 growth is driven by increasing demand for its unique portfolio of prescription medications, including Natesto and ZolpiMist, as well as its growing presence in the pediatrics and orthopedics markets. Additionally, strategic partnerships and acquisitions have expanded its product offerings and geographic reach, contributing to its rapid growth.

Aytu Consumer Health

Expected Growth: 3.0%

Aytu Consumer Health's 3.0 growth is driven by increasing demand for over-the-counter (OTC) healthcare products, strategic acquisitions, and expansion into new markets. The segment benefits from a strong brand portfolio, including Zolpimist and Cerevate, and a growing e-commerce presence. Additionally, Aytu's focus on product innovation and marketing efforts contribute to its growth momentum.

7. Detailed Products

Natesto

A nasal gel for testosterone replacement therapy in hypogonadal men.

Tuzistra XR

An extended-release oral suspension for the treatment of cough and upper respiratory symptoms.

ZolpiMist

An oral spray for the treatment of insomnia.

Cefaclor

An oral antibiotic for the treatment of bacterial infections.

Karbate

A prescription prenatal vitamin for pregnant women.

8. Aytu BioPharma, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Aytu BioPharma, Inc. operates in a niche market with limited substitutes, but the threat of substitutes is still present due to the ongoing research and development in the pharmaceutical industry.

Bargaining Power Of Customers

Aytu BioPharma, Inc. has a diverse customer base, which reduces the bargaining power of individual customers. Additionally, the company's products are specialized, making it difficult for customers to switch to alternative suppliers.

Bargaining Power Of Suppliers

Aytu BioPharma, Inc. relies on a limited number of suppliers for its raw materials and services. While the company has some bargaining power due to its size, suppliers still have some leverage in negotiations.

Threat Of New Entrants

The pharmaceutical industry has high barriers to entry, including significant regulatory hurdles and high research and development costs. This makes it difficult for new entrants to enter the market and compete with established players like Aytu BioPharma, Inc.

Intensity Of Rivalry

The pharmaceutical industry is highly competitive, with many established players competing for market share. Aytu BioPharma, Inc. faces intense competition from other companies with similar products and pipelines.

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

Value
Debt Weight 29.36%
Debt Cost 3.95%
Equity Weight 70.64%
Equity Cost -2.22%
WACC -0.41%
Leverage 41.57%

11. Quality Control: Aytu BioPharma, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Stock-Card
Supernus Pharmaceuticals

A-Score: 5.9/10

Value: 9.1

Growth: 6.0

Quality: 5.9

Yield: 0.0

Momentum: 8.5

Volatility: 5.7

1-Year Total Return ->

View Full Report
Stock-Card
Aytu BioPharma

A-Score: 4.8/10

Value: 9.4

Growth: 4.7

Quality: 4.2

Yield: 0.0

Momentum: 9.0

Volatility: 1.3

1-Year Total Return ->

View Full Report
Stock-Card
Amphastar Pharmaceuticals

A-Score: 4.6/10

Value: 6.7

Growth: 8.9

Quality: 6.3

Yield: 0.0

Momentum: 1.0

Volatility: 4.7

1-Year Total Return ->

View Full Report
Stock-Card
Journey Medical

A-Score: 4.2/10

Value: 6.6

Growth: 3.3

Quality: 4.2

Yield: 0.0

Momentum: 9.0

Volatility: 2.0

1-Year Total Return ->

View Full Report
Stock-Card
Alimera Sciences

A-Score: 3.8/10

Value: 7.3

Growth: 4.7

Quality: 4.3

Yield: 0.0

Momentum: 6.0

Volatility: 0.7

1-Year Total Return ->

View Full Report
Stock-Card
PetIQ

A-Score: 3.7/10

Value: 3.7

Growth: 7.7

Quality: 3.1

Yield: 0.0

Momentum: 6.0

Volatility: 1.7

1-Year Total Return ->

View Full Report

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

2.61$

Current Price

2.6$

Potential

0.00%

Expected Cash-Flows